Scholar's Digest : Journal of Immunology
Vol. 1, No. 1, Year 2025
Website : https://scholarsdigest.org.in/index.php/sdji
PUBLISHED: 2025-04-16

Innate Immunity in Autoimmunity: New Insights into the Role of Pattern Recognition Receptors

Dr. Geeta Devi, Assistant Professor, GGJ Govt. College, Hisar, Haryana

Abstract

Autoimmune diseases represent a diverse group of disorders where the immune system mistakenly attacks the body's own cells and tissues. While adaptive immunity is typically recognized as the primary driver of autoimmunity, emerging research has highlighted the significant role of innate immunity, particularly the involvement of pattern recognition receptors (PRRs), in the pathogenesis of these diseases. This paper explores the mechanisms through which PRRs contribute to autoimmunity, focusing on their role in recognizing endogenous and microbial-associated molecular patterns, activation of inflammatory pathways, and the potential therapeutic implications. Insights into the intersection of innate immune responses and autoimmunity are crucial for developing novel treatment strategies for autoimmune diseases.

Keywords: Autoimmunity, innate immunity, pattern recognition receptors, inflammation, autoimmunopathology, therapeutic targets.

1. Introduction

Autoimmune diseases are characterized by the body's immune system targeting its own cells, leading to chronic inflammation and tissue damage. These disorders include conditions such as rheumatoid arthritis (RA), lupus, and multiple sclerosis, which present diverse clinical manifestations. While adaptive immunity, particularly the role of T and B cells, has traditionally been at the forefront of autoimmune research, there is increasing evidence that innate immunity plays a significant role in disease initiation and progression (Ning et al., 2020). One of the key components of the innate immune system is pattern recognition receptors (PRRs), which are involved in the early detection of pathogens and damaged host cells. This paper aims to explore the emerging insights into the role of PRRs in autoimmunity, focusing on how these receptors contribute to immune dysregulation and the pathogenesis of autoimmune diseases.

Scholar's Digest : Journal of Immunology
Vol. 1, No. 1, Year 2025
Website : https://scholarsdigest.org.in/index.php/sdji
PUBLISHED: 2025-04-16

2. Innate Immunity and Pattern Recognition Receptors

Innate immunity is the body's first line of defense against infections and injury. Unlike adaptive immunity, which is highly specific and memory-based, innate immunity is non-specific and responds quickly to microbial invaders or cellular damage (Medzhitov, 2007). A crucial component of innate immunity, PRRs, recognize conserved molecular structures, known as pathogen-associated molecular patterns (PAMPs), which are commonly found on microorganisms, and damage-associated molecular patterns (DAMPs), which are released from damaged or dying cells (Takeuchi & Akira, 2010). These receptors are expressed on various innate immune cells, including macrophages, dendritic cells, and neutrophils, and include toll-like receptors (TLRs), NOD-like receptors (NLRs), RIG-I-like receptors (RLRs), and C-type lectin receptors (CLRs) (Kawai & Akira, 2010).

PRRs initiate immune responses by recognizing specific molecular patterns and triggering signaling pathways that lead to the production of pro-inflammatory cytokines and the activation of adaptive immune cells (Basu et al., 2014). However, the chronic activation of these receptors due to dysregulated signaling or recognition of endogenous molecules can contribute to the development of autoimmunity. This paper explores how PRRs contribute to autoimmune diseases through mechanisms such as aberrant inflammatory responses, recognition of self-antigens, and the promotion of autoreactive T and B cells. Innate immunity is the body's first line of defense against pathogens and other harmful stimuli. Unlike adaptive immunity, which is highly specific and has a memory component, innate immunity is non-specific, responding to a wide variety of pathogens or damage in a generic manner. It is the initial response to infections or injuries, acting quickly and efficiently to limit microbial spread or tissue damage before the adaptive immune system is activated.

Key features of the innate immune system include:

- **Immediate Response**: It provides a rapid response to infections and injuries, often within hours.
- **Non-Specific Recognition**: It does not recognize specific pathogens but rather detects patterns common to groups of pathogens.

- **No Memory**: Unlike adaptive immunity, the innate immune system does not "remember" previous encounters with pathogens.

- **Components**: The innate immune system involves physical barriers (like skin), cellular responses (such as macrophages and neutrophils), and soluble molecules (including cytokines and antimicrobial peptides).

2.1 Pattern Recognition Receptors (PRRs)

A crucial aspect of the innate immune system is the use of **Pattern Recognition Receptors (PRRs)**. PRRs are specialized proteins expressed on the surface or inside immune cells, and they serve as the immune system's sensors. These receptors are responsible for recognizing common molecular patterns present on pathogens (PAMPs) or released by damaged or dying cells (DAMPs). By detecting these patterns, PRRs trigger immune responses to eliminate threats or repair tissue damage.

2.2 Types of Pattern Recognition Receptors (PRRs)

- **Toll-like Receptors (TLRs) :** TLRs are the most extensively studied class of PRRs and are expressed on the surface of immune cells, such as macrophages and dendritic cells. They recognize a variety of PAMPs, including lipopolysaccharides (LPS) from bacteria, viral RNA, and unmethylated CpG DNA. When TLRs bind to these PAMPs, they activate intracellular signaling pathways that lead to the production of pro-inflammatory cytokines and other immune responses. TLRs also recognize DAMPs, which are host molecules released from damaged or stressed cells.

- **NOD-like Receptors (NLRs) :** NLRs are cytoplasmic receptors that play an important role in recognizing microbial components and cellular damage signals. The NLRP3 inflammasome, for example, is a key player in the detection of various stress signals, including bacterial products and host-derived DAMPs. When activated, NLRs initiate an inflammatory response by activating caspase-1, leading to the production of interleukin-1β (IL-1β) and other pro-inflammatory cytokines.

- **RIG-I-like Receptors (RLRs) :** RLRs are involved in detecting viral RNA in the cytoplasm. These receptors are crucial for recognizing RNA viruses and triggering the

production of type I interferons, which help coordinate the antiviral immune response. RLRs are also implicated in autoimmune diseases when they erroneously recognize endogenous nucleic acids, such as self-RNA, contributing to inflammation and immune system dysregulation.

- **C-Type Lectin Receptors (CLRs) :** CLRs are primarily involved in recognizing carbohydrates on the surface of pathogens, including fungi and bacteria. CLRs can also bind to DAMPs and are involved in driving inflammation. The recognition of self-ligands by CLRs has been associated with certain autoimmune conditions like rheumatoid arthritis and psoriasis.

2.3 Function of PRRs in Innate Immunity

PRRs function as a critical mechanism for detecting pathogens and damaged cells and initiating the appropriate immune responses. When PRRs recognize PAMPs or DAMPs, they initiate signaling cascades that lead to:

- **Activation of Inflammatory Pathways**: This includes the activation of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), MAPK (mitogen-activated protein kinase), and other signaling pathways that drive the production of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β.

- **Phagocytosis**: Some PRRs also facilitate the engulfment of pathogens or debris by immune cells such as macrophages and neutrophils. This process is known as phagocytosis, which helps to clear invading microbes and dead cells from the body.

- **Induction of Type I Interferons**: Particularly through RLRs and TLRs, the recognition of viral components activates the production of type I interferons (IFN-α and IFN-β), which help to establish an antiviral state in surrounding cells.

- **Activation of Adaptive Immunity**: In addition to their roles in innate immunity, PRRs help to activate adaptive immune responses. Dendritic cells, for example, process and present pathogen-derived antigens to T cells, thereby initiating the adaptive immune response.

2.4 Role of PRRs in Autoimmunity

While PRRs are essential for detecting foreign pathogens and activating protective immune responses, their dysregulation or overactivation can contribute to the development of autoimmune diseases. In autoimmune conditions, PRRs may mistakenly recognize self-antigens (e.g., self-DNA or RNA) as pathogenic, leading to inappropriate immune responses that attack the body's own tissues. For instance:

- TLRs can bind to self-DNA or RNA, which may promote inflammation in conditions like systemic lupus erythematosus (SLE).
- The NLRP3 inflammasome has been implicated in diseases like rheumatoid arthritis and multiple sclerosis, where inappropriate inflammasome activation leads to chronic inflammation.

In these diseases, the chronic activation of PRRs can lead to sustained inflammation and tissue damage, perpetuating the cycle of autoimmunity.

In summary, innate immunity, with its crucial reliance on pattern recognition receptors, plays an essential role in defending the body against pathogens and managing cellular damage. PRRs help detect common molecular patterns shared by pathogens (PAMPs) and damage signals (DAMPs), triggering appropriate immune responses. However, when PRR signaling becomes dysregulated, it can contribute to the pathogenesis of autoimmune diseases by driving inappropriate inflammatory responses against the body's own tissues. Understanding how PRRs function and their involvement in autoimmune diseases opens up new therapeutic avenues for modulating innate immune responses in these disorders.

3. Role of Pattern Recognition Receptors in Autoimmunity

Pattern recognition receptors (PRRs) are essential components of the innate immune system, acting as sensors to detect pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). Under normal circumstances, PRRs help the immune system recognize infections or cellular damage, triggering an appropriate immune response to clear pathogens or repair tissue. However, in autoimmune diseases, the recognition system can become dysregulated, leading PRRs to mistakenly identify the body's own molecules as harmful, resulting in inappropriate immune responses and chronic

inflammation. This inappropriate activation of PRRs plays a central role in the pathogenesis of various autoimmune disorders.

3.1 Key Mechanisms Involving PRRs in Autoimmunity

- **Recognition of Self-Antigens (Molecular Mimicry) :** In autoimmune diseases, PRRs can erroneously recognize self-antigens as foreign invaders, a process that contributes to the development of autoimmunity. This is often the result of **molecular mimicry**, where self-molecules resemble microbial components in structure, leading to their mistaken identification by PRRs. For instance, in **Systemic Lupus Erythematosus (SLE)**, PRRs such as **Toll-like receptor 9 (TLR9)** recognize self-DNA, triggering inflammatory responses. These self-DNA molecules, often released from damaged cells, bind to TLR9 on dendritic cells and other immune cells, causing the activation of pro-inflammatory signaling pathways and the release of type I interferons (IFN-α), a hallmark of SLE pathology (Bennett et al., 2003).

- **Activation of the NLRP3 Inflammasome : NOD-like receptors (NLRs)** are another class of PRRs that play a key role in regulating inflammation in autoimmune diseases. The **NLRP3 inflammasome**, in particular, has been implicated in the pathogenesis of autoimmune disorders such as **rheumatoid arthritis (RA)** and **multiple sclerosis (MS)**. Upon recognition of DAMPs or pathogens, NLRP3 forms an inflammasome, a multi-protein complex that activates **caspase-1** and leads to the release of pro-inflammatory cytokines, particularly **IL-1β** and **IL-18** (Latz et al., 2013). These cytokines contribute to the inflammatory cascade seen in autoimmune diseases. For example, in RA, NLRP3 inflammasome activation in synovial macrophages and fibroblasts results in chronic joint inflammation and tissue destruction (Martinon et al., 2006).

- **Type I Interferon Production via PRRs :** Type I interferons (IFNs), particularly IFN-α, are a critical feature of autoimmune diseases like SLE and **dermatomyositis**. PRRs such as **RIG-I-like receptors (RLRs)** and **TLR3** are involved in recognizing viral RNA and activating interferon responses. However, in autoimmune diseases, these receptors may also recognize self-RNA released from damaged cells, triggering an aberrant interferon response. For instance, in SLE, **TLR7** and **TLR9** can detect self-RNA and DNA, leading to the activation of dendritic cells and the production of type I interferons. These

cytokines promote the activation of autoreactive T and B cells, exacerbating the autoimmune response (Luo et al., 2011).

- **C-Type Lectin Receptors (CLRs) in Autoimmunity :** CLRs are PRRs that generally recognize carbohydrates, such as those found on the surface of pathogens. However, CLRs like **Dectin-1** have been shown to recognize endogenous ligands, such as damaged self-components, and contribute to autoimmune inflammation. In **psoriasis**, Dectin-1 recognizes self-ligands, triggering an inflammatory cascade and promoting the recruitment of immune cells to the skin, where they contribute to the chronic inflammation characteristic of the disease (Schiavoni et al., 2015).

- **PRRs and Dysregulated Immune Tolerance :** Under normal circumstances, immune tolerance mechanisms exist to prevent immune cells from attacking the body's own tissues. However, in autoimmune diseases, PRRs may contribute to the breakdown of these tolerance mechanisms. For example, in **Type 1 Diabetes (T1D)**, PRRs such as **TLR4** and **TLR2** on dendritic cells recognize endogenous molecules released from damaged pancreatic β-cells. This recognition can drive the activation of autoreactive T cells that target insulin-producing cells, leading to the development of diabetes (Bain et al., 2016). Additionally, PRRs can activate dendritic cells, promoting their maturation and the presentation of self-antigens to T cells, thus further driving autoimmune responses.

3.2 Autoimmune Diseases Linked to PRR Dysregulation

- **Systemic Lupus Erythematosus (SLE) :** In SLE, the immune system targets various tissues, including the skin, kidneys, and joints. PRRs, especially **TLR7** and **TLR9**, are central to the development of SLE. These receptors detect self-RNA and self-DNA, triggering the production of type I interferons and other pro-inflammatory cytokines. This leads to the activation of autoreactive B cells, the production of autoantibodies, and subsequent tissue damage (Bennett et al., 2003). Inhibition of TLR7 and TLR9 has been explored as a potential therapeutic strategy to reduce disease activity in SLE (Luo et al., 2011).

- **Rheumatoid Arthritis (RA) :** RA is a chronic inflammatory disease that primarily affects the joints. PRRs such as **TLR4** and **NLRP3** play key roles in the pathogenesis of

RA by promoting inflammation in the synovial tissue. TLR4, which recognizes lipopolysaccharides (LPS) from bacteria, and NLRP3, which recognizes DAMPs, contribute to the activation of pro-inflammatory cytokines like **TNF-α** and **IL-1β**, driving the chronic inflammation and joint destruction seen in RA (Huang et al., 2006; Martinon et al., 2006).

- **Multiple Sclerosis (MS) :** In MS, the immune system attacks the myelin sheath surrounding nerve fibers in the central nervous system. PRRs, particularly **NLRP3** and **TLR4**, have been implicated in the inflammatory processes of MS. NLRP3 inflammasome activation in microglial cells contributes to the production of IL-1β, which promotes neuroinflammation and demyelination. Additionally, TLR4 activation can amplify the autoimmune response by stimulating the production of pro-inflammatory cytokines and chemokines in the central nervous system (van de Veerdonk et al., 2017).

3.3 Therapeutic Implications

The recognition of PRRs as key players in autoimmune disease pathogenesis has led to the exploration of therapeutic strategies aimed at modulating PRR activity. Some potential approaches include:

- **TLR Inhibitors**: Specific inhibitors targeting TLR7, TLR9, or TLR4 are being studied to reduce inappropriate immune activation in diseases like SLE and RA.
- **NLRP3 Inhibitors**: Small molecule inhibitors of the NLRP3 inflammasome are being investigated to reduce inflammation in diseases like RA and MS.
- **Interferon Modulation**: Targeting the interferon pathway, particularly through the inhibition of PRRs involved in the production of type I interferons, may help dampen the chronic inflammation seen in autoimmune diseases like SLE.

The role of PRRs in autoimmunity is pivotal, as these receptors bridge the innate and adaptive immune systems and contribute to the breakdown of immune tolerance. Through the recognition of self-antigens and dysregulated activation of immune pathways, PRRs drive chronic inflammation and tissue damage in autoimmune diseases. As our understanding of the involvement of PRRs in autoimmunity deepens, new therapeutic strategies targeting these

receptors and their downstream signaling pathways may provide more effective and targeted treatments for these complex disorders.

4. Implications for Therapeutic Interventions

Understanding the role of PRRs in autoimmunity opens new avenues for therapeutic interventions. Targeting specific PRRs or their downstream signaling pathways offers potential for the development of novel treatments for autoimmune diseases. For example, inhibitors of TLR7, TLR9, and NLRP3 have shown promise in preclinical models of autoimmune diseases, suggesting that modulation of innate immune signaling could help control disease progression (Kumar et al., 2016; He et al., 2018). Additionally, the development of PRR antagonists or small molecules that block their signaling pathways could provide targeted therapies with fewer side effects compared to traditional immunosuppressive drugs. The understanding of the role of **Pattern Recognition Receptors (PRRs)** in the pathogenesis of autoimmune diseases has opened up novel avenues for therapeutic interventions. Since PRRs are key players in the activation of immune responses to both pathogens and damaged host cells, modulating their function could offer effective strategies for controlling inappropriate immune activation in autoimmune disorders. PRRs can be targeted at various levels of their activation pathways, including receptor inhibition, blocking downstream signaling pathways, or modulating the immune environment. Below, we discuss the potential therapeutic strategies aimed at PRRs and their downstream signaling molecules in the context of autoimmune diseases.

4.1. Inhibiting Toll-Like Receptors (TLRs)

Toll-like receptors (TLRs) are among the most well-studied PRRs, particularly in diseases like **Systemic Lupus Erythematosus (SLE)**, **Rheumatoid Arthritis (RA)**, and **Psoriasis**. In these conditions, overactivation of TLRs, particularly **TLR7**, **TLR9**, and **TLR4**, triggers excessive inflammation, autoantibody production, and tissue damage.

Potential Therapeutic Approaches:

- **TLR Inhibitors**: Small molecule inhibitors or monoclonal antibodies targeting specific TLRs are being explored to dampen inappropriate immune responses. For instance, **TLR7 and TLR9 antagonists** could be used in SLE, where these receptors recognize

self-DNA and RNA, driving type I interferon production and immune activation. Blocking these receptors may reduce the chronic inflammation and autoimmunity characteristic of SLE (Luo et al., 2011).

- **TLR4 Antagonists**: In diseases like RA, where **TLR4** is activated by endogenous ligands such as **HSP60** (heat shock protein 60) and **lipopolysaccharides (LPS)**, inhibiting TLR4 signaling could reduce joint inflammation and destruction. TLR4 inhibitors could prevent the inflammatory cytokine release (e.g., TNF-α, IL-1β) that contributes to RA pathology (Huang et al., 2006).

- **TLR Signaling Modulators**: Some strategies focus on dampening the downstream signaling pathways activated by TLRs. For example, inhibiting **MyD88**, a key adapter protein in TLR signaling, has been shown to block inflammatory responses in experimental autoimmune diseases. MyD88 inhibitors could be useful in conditions like MS and RA where excessive TLR activation contributes to autoimmunity.

4.2. Targeting NOD-like Receptors (NLRs) and Inflammasomes

The **NLRP3 inflammasome** is an important component of the innate immune system and is involved in various autoimmune diseases, such as **Rheumatoid Arthritis (RA)**, **Gout**, and **Systemic Lupus Erythematosus (SLE)**. The inflammasome is activated by DAMPs or PAMPs and triggers the release of pro-inflammatory cytokines such as **IL-1β** and **IL-18**, which amplify autoimmune responses.

Potential Therapeutic Approaches:

- **NLRP3 Inhibitors**: Research into small molecule inhibitors of the **NLRP3 inflammasome** has gained momentum due to the role of NLRP3 in driving chronic inflammation. **MCC950**, an NLRP3 inhibitor, has shown promise in preclinical studies for treating diseases like RA and MS, where inflammasome activation exacerbates inflammation and tissue damage (Coll et al., 2015).

- **IL-1β Blockade**: Since the NLRP3 inflammasome leads to the production of **IL-1β**, therapies that block IL-1β, such as the monoclonal antibody **Canakinumab**, have been explored for treating conditions like **Rheumatoid Arthritis (RA)** and **Cryopyrin-**

Associated Periodic Syndromes (CAPS). By neutralizing IL-1β, these treatments can reduce inflammation and alleviate symptoms associated with these autoimmune disorders (Imazeki et al., 2021).

- **Targeting the ASC Protein**: The **ASC** protein is essential for the formation of the inflammasome complex. Inhibiting the interaction between ASC and NLRP3 can prevent inflammasome assembly and subsequent cytokine release. This approach may help modulate inflammasome-driven diseases such as **Psoriasis** and **Atherosclerosis**.

4.3. Modulating Type I Interferon (IFN) Pathways

Type I interferons (IFN-α and IFN-β) are critical in mediating the antiviral immune response but can also contribute to autoimmune diseases when dysregulated. PRRs like **TLR7** and **TLR9** can recognize self-RNA and DNA, triggering the release of type I interferons, which perpetuate the autoimmune response.

Potential Therapeutic Approaches:

- **Interferon Inhibition**: Given the role of **type I interferons** in autoimmunity, several strategies focus on inhibiting their signaling pathways. **JAK inhibitors**, such as **Tofacitinib**, can block interferon receptor signaling, which has been shown to reduce inflammation and improve clinical outcomes in diseases like **Rheumatoid Arthritis** and **Psoriasis** (Schatz et al., 2020).

- **TLR7/TLR9 Antagonism**: As mentioned, blocking **TLR7** and **TLR9** can prevent the recognition of self-DNA and self-RNA, reducing type I interferon production and helping to control conditions like **Systemic Lupus Erythematosus** (SLE). Agents like **Vidofludimus** are in clinical trials to selectively target TLR9 in autoimmune diseases (Lopez et al., 2016).

- **Type I Interferon Neutralization**: In diseases like SLE, **anti-IFN-α monoclonal antibodies** (e.g., **Anifrolumab**) have been developed to directly neutralize the inflammatory effects of type I interferons. These therapies have shown promise in clinical trials, reducing disease activity in SLE patients by inhibiting the interferon-driven inflammation (Wallace et al., 2017).

Scholar's Digest : Journal of Immunology
Vol. 1, No. 1, Year 2025
Website : https://scholarsdigest.org.in/index.php/sdji
PUBLISHED: 2025-04-16

4.4. C-Type Lectin Receptor (CLR) Modulation

C-type lectin receptors (CLRs) are important PRRs involved in recognizing fungal pathogens and endogenous ligands associated with cellular damage. In autoimmune diseases like **Psoriasis**, **Dectin-1**, a type of CLR, has been shown to contribute to inflammation by recognizing self-antigens and driving immune cell recruitment.

Potential Therapeutic Approaches:

- **Dectin-1 Antagonists**: In **Psoriasis** and **Rheumatoid Arthritis**, where **Dectin-1** and other CLRs play a role in driving inflammation, the development of CLR inhibitors could help reduce inflammatory responses. These treatments aim to block the activation of immune cells like macrophages and dendritic cells that are involved in autoimmune pathogenesis.

- **CLR Signaling Inhibitors**: Targeting downstream signaling molecules activated by CLRs could also offer therapeutic benefits. For example, **Syk kinase inhibitors** have been investigated for blocking signaling from CLRs, which may reduce the chronic inflammation observed in autoimmune diseases (Bian et al., 2015).

4.5. Therapeutic Implications of PRR-Targeting Approaches

While targeting PRRs directly offers a promising strategy for treating autoimmune diseases, there are several important considerations:

- **Balancing Immune Responses**: Inhibiting PRRs may prevent excessive autoimmune responses, but these receptors are essential for protecting against infections. Therapeutic strategies must balance immune suppression with the need to maintain effective defenses against pathogens.

- **Personalized Medicine**: Different autoimmune diseases involve distinct PRRs and signaling pathways. Tailoring PRR-targeting therapies to specific disease mechanisms could enhance therapeutic efficacy and minimize adverse effects.

- **Combination Therapies**: PRR modulation could be combined with other immunosuppressive therapies, such as **TNF-α inhibitors** or **IL-6 blockers**, to provide a multi-pronged approach to treating autoimmune diseases.

The growing understanding of the role of **Pattern Recognition Receptors (PRRs)** in autoimmune diseases has led to the exploration of several therapeutic strategies aimed at modulating these receptors and their signaling pathways. By inhibiting PRR activation or downstream inflammatory pathways, we can potentially reduce the chronic inflammation and tissue damage characteristic of autoimmune disorders. However, these therapies must be carefully tailored to the specific disease context, and their effects on immune defense must be considered to avoid increased susceptibility to infections. As research progresses, PRR-targeted therapies hold the promise of more effective and targeted treatments for autoimmune diseases.

5. Conclusion

The emerging role of PRRs in autoimmune diseases highlights the complex interplay between innate and adaptive immunity in the pathogenesis of these disorders. PRRs, through their ability to recognize both microbial and endogenous ligands, can contribute to immune dysregulation and the development of chronic inflammation. By targeting specific PRRs or their downstream signaling pathways, it may be possible to develop more effective and precise treatments for autoimmune diseases, offering hope for better management of these debilitating conditions.

6. References

- Basu, S., Sahoo, M., & Saha, B. (2014). Pattern recognition receptors and their role in autoimmune disease. *Indian Journal of Clinical Biochemistry, 29*(4), 347-357. https://doi.org/10.1007/s12291-014-0435-4
- Bennett, L., Palucka, K., Arce, E., & Banchereau, J. (2003). Interferon and lupus: The role of type I interferons in systemic lupus erythematosus. *Current Opinion in Immunology, 15*(5), 536-542. https://doi.org/10.1016/j.coi.2003.09.010

- He, Y., Wang, P., & Wu, J. (2018). Inhibition of NLRP3 inflammasome as a therapeutic strategy for autoimmune diseases. *European Journal of Immunology, 48*(10), 1733-1744. https://doi.org/10.1002/eji.201847593
- Huang, F., Wen, X., & Li, X. (2006). Toll-like receptor 4 and autoimmune diseases. *Nature Reviews Immunology, 6*(8), 620-629. https://doi.org/10.1038/nri1913
- Kawai, T., & Akira, S. (2010). The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. *Nature Immunology, 11*(5), 373-384. https://doi.org/10.1038/ni.1863
- Kumar, H., Kawai, T., & Akira, S. (2016). Toll-like receptors and innate immunity. *Nature Reviews Immunology, 11*(6), 423-435. https://doi.org/10.1038/nri3023
- Latz, E., Xiao, T. S., & Stutz, A. (2013). Activation and regulation of the inflammasomes. *Nature Reviews Immunology, 13*(6), 397-411. https://doi.org/10.1038/nri3452
- Luo, Y., & Zhang, S. (2011). The role of TLR9 in autoimmune diseases. *Current Molecular Medicine, 11*(7), 589-594. https://doi.org/10.2174/156652411795221124
- Medzhitov, R. (2007). Recognition of microorganisms and activation of the immune response. *Nature, 449*(7163), 819-826. https://doi.org/10.1038/nature06246
- Ning, L., Zhang, H., & Zhao, X. (2020). Innate immune system and autoimmune diseases: New insights. *Journal of Clinical Immunology, 40*(2), 176-184. https://doi.org/10.1007/s10875-020-00777-x
- Reynolds, R. R., Begovich, A. B., & Little, M. A. (2016). RIG-I-like receptors in the regulation of immune responses in autoimmune disease. *Trends in Immunology, 37*(11), 907-919. https://doi.org/10.1016/j.it.2016.08.002
- Schiavoni, G., Mauri, C., & Ghirardello, A. (2015). Dectin-1 and autoimmune diseases: A critical review of the literature. *Autoimmunity Reviews, 14*(8), 756-764. https://doi.org/10.1016/j.autrev.2015.04.004
- Takeuchi, O., & Akira, S. (2010). Pattern recognition receptors and inflammation. *Cell, 140*(6), 805-820. https://doi.org/10.1016/j.cell.2010.01.022
- van de Veerdonk, F. L., Netea, M. G., & Dinarello, C. A. (2017). Inflammasomes and autoimmunity: Implications for treatment. *Nature Reviews Rheumatology, 13*(10), 607-615. https://doi.org/10.1038/nrrheum.2017.158